CN Patent

CN113262221A — 使用川地匹坦的治疗方法

Assigned to Vanda Pharmaceuticals Inc · Expires 2021-08-17 · 5y expired

What this patent protects

本申请涉及一种使用川地匹坦的治疗方法，更具体地涉及使用川地匹坦治疗对川地匹坦疗法有响应的疾病或病况的方法。

USPTO Abstract

本申请涉及一种使用川地匹坦的治疗方法，更具体地涉及使用川地匹坦治疗对川地匹坦疗法有响应的疾病或病况的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN113262221A
Jurisdiction: CN
Classification: —
Expires: 2021-08-17
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.